Nkarta doses first patients in NKX019 Ph1; NKX101 initial data guided to 1H 2022

Nkarta, Inc.

First patients dosed in Phase 1 trial of NKX019 for CD19+ B-cell malignancies (NHL, CLL, B-ALL).
Initial data from NKX019 trial expected in 2022.
Initial data from NKX101 Phase 1 in AML/MDS now expected in first half of 2022 (previously anticipated earlier).
NKX101 cadence affected by haplomatched donor cell use, staggered enrollment, and COVID-19 disruptions.
Protocol amended to allow off-the-shelf or haplomatched cells and to shorten patient stagger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.